Tuberculosis Treatment Drugs Market Expected to Reach $3.2 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Tuberculosis Treatment Drugs Market," The tuberculosis treatment drugs market size was valued at $1.9 billion in 2021, and is estimated to reach $3.2 billion by 2031, growing at a CAGR of 5.3% from 2022 to 2031.

The major Tuberculosis treatment drugs market trends includes, is increase in prevalence of Tuberculosis cases which drive growth of the market. For instance, according to a report from World Health Organization 2023, it stated that about one-fourth of the world’s population is infected with Mycobacterium tuberculosis (Mtb), of whom 5-10% will develop TB disease during their lifetime. Furthermore, rise in number of drug approvals, and increase in awareness about prevention, diagnosis & treatment options available drives the market growth. Thus, surge in prevalence of tuberculosis cases, rise in drug approvals, and increase in awareness are anticipated to drive the growth of market.  

Further, a rise in regulatory approvals for treating tuberculosis is expected to drive growth during the Tuberculosis treatment drugs market forecast. For instance, in October 2021, Otsuka Pharmaceutical Co., Ltd., received European Commission approval for Deltyba (delamanid) 25-mg dispersible tablet formulation for the treatment of tuberculosis. Thus, a rise in the number of product approvals for treating tuberculosis is expected to drive the growth during Tuberculosis treatment drugs market analysis. 

Furthermore, the introduction of new treatment guidelines for tuberculosis (TB) by the healthcare government is likely to boost the market growth for TB drugs. These guidelines are often based on the latest scientific evidence and are designed to improve the standard of care for patients with TB. These guidelines provide clear and evidence-based recommendations for diagnosis, treatment, and follow-up care. The guidelines can help healthcare providers to deliver more effective care and improve patient outcomes. In addition, these guidelines help in the standardization of the treatment; by ensuring that all patients receive the same high-quality care regardless of where they live which further drives the market growth.  

Furthermore, rise in adoption of strategies such as agreement and partnership by key players of market to cater to the demand of tuberculosis treatment drugs and innovation is expected to propel the market expansion. For instance, in October 2022, Lupin Limited announced agreements with Unitaid, the Aurum Institute, the Clinton Health Access Initiative (CHAI), and other global procurement agencies to support tuberculosis prevention treatment and introduction of two new fixed-dose formulations, which will be supplied to many low-and middle-income countries with a large burden of TB. Thus, a rise in the adoption of such key strategies is anticipated to contribute to the growth of the market.

Moreover, increased awareness about early diagnosis and treatment of mycobacterium tuberculosis infections, and increased access to healthcare services, have contributed to the growth of the tuberculosis treatment drugs market. In addition, increase in government fundings for research and development of new early diagnostic kits is anticipated to drive the Tuberculosis treatment drugs industry.  

However, stringent regulations regarding approval of tuberculosis drugs and adverse side effects such as liver toxicity, vision problem, hearing loss, neuropathy, and hematological effects associated with tuberculosis drugs are the factors restraining the growth of the tuberculosis treatment drugs market size. In addition, as patents of some tuberculosis treatment drug expire, generic versions become available, which can reduce the cost of therapy. 

On the basis of disease type, the market is categorized into active tuberculosis and latent tuberculosis. The active tuberculosis segment accounted for the largest share in 2021, and is expected to witness highest CAGR during the forecast period, owing to higher prevalence of tuberculosis cases across the globe and rise in number of key players offering novel medications.  

On the basis of therapy type, the market is categorized into first line therapy and second line therapy. The first line therapy segment accounted for largest Tuberculosis treatment drugs market share in 2021 and is expected to witness highest CAGR during the forecast period owing to higher usage of first line therapy drugs for treating tuberculosis in combinations as they have less side effects as compared to second line therapy drugs which is anticipated to drive the market growth in the forecast period. 

Region wise, North America accounted for largest Tuberculosis treatment drugs market share in 2021 and is expected to remain dominant during the forecast period owing to high healthcare awareness along with presence of well-developed healthcare infrastructure, rise in prevalence of tuberculosis-infected cases, and ease of drug availability with large number of trained medical professionals which drive the growth of the tuberculosis treatment drugs market.

However, Asia-Pacific is anticipated to witness notable growth, owing to higher prevalence of tuberculosis drug treatment agents, increase in drug resistant TB cases and number of pipeline medications for treating active and latent tuberculosis conditions, thereby driving the growth of market during the forecast period.   

Key findings of the study 

• On the basis of disease type, the active tuberculosis segment dominated the Tuberculosis treatment drugs industry in terms of revenue in 2021. 
• On the basis of therapy type, first-line therapy segment dominated the market in terms of revenue in 2021. 
• On the basis of distribution channel, the Drug Stores and Retail Pharmacies segment dominated the market in terms of revenue in 2021. However, the online providers segment is anticipated to grow at the highest CAGR during the forecast period. 
• Region wise, North America generated the largest revenue in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.